Schedule 13G ownership disclosure
Stoke Therapeutics Inc
Common Stock · CUSIP: 86150R107
Event date: 2025-03-31
- Filing-level shares
- 2,743,502
- Percent of class
- 5.1%
- BlackRock Portfolio Management LLC
Shares: 2,743,502 · Class: 5.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0002052113-25-000328
- Form type
- SCHEDULE 13G
- Filer
- BlackRock Portfolio Management LLC
- CIK
- CIK 2052113
- Filed
- Apr 15, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership